Linvoseltamab

Generic Name: Linvoseltamab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: M3CPC50MZS

Background: Linvoseltamab is an investigational bispecific antibody. It promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta

Zacks.com highlights biotech stocks, focusing on Q4 earnings and regulatory updates. Moderna beat earnings estimates, reaffirmed 2024 sales guidance, and expects RSV vaccine approval. RAPT Therapeutics faced a clinical hold due to a liver failure case. Iovance surged after FDA approval for melanoma treatment. Sarepta seeks label expansion for DMD drug. Regeneron's myeloma drug gets Priority Review.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy